KineMed, Inc. And Camino Partnership Announce Collaboration To Create Portfolio Of Clinical Drug Candidates
EMERYVILLE, Calif.--(BUSINESS WIRE)--KineMed, Inc. and Camino Partnership, LLC today announced they are entering into a strategic partnership to locate and acquire control of a portfolio of new drug and targeted drug candidates. Once acquired, the collaboration will apply KineMed’s dynamic proteomics technology to carry out rapid proof-of-concept clinical studies for subsequent out-licensing to pharmaceutical companies. The initial therapeutic areas of focus will be oncology, neurodegenerative disorders, muscle wasting and fibrosis, particularly fibrosis of the liver. The collaboration intends to carry out de-risking proof-of-concept studies on up to six compounds over a three-year period.
“Camino is focused on reducing the downside risk and creating value by accelerating the drug development process. We are delighted to collaborate with KineMed as they provide unique clinical insights into drug target engagement and processes of disease modification that can advantage Camino in accomplishing these goals.”
“By partnering with Camino, we are executing on our strategy to produce a pipeline of high-value drug candidates rapidly by leveraging the strength of our dynamic proteomics platform with Camino’s financial support and extensive global experience in developing drugs,” said Patrick Doyle, president of KineMed.
Harish Dave, managing partner of Camino, added, “Camino is focused on reducing the downside risk and creating value by accelerating the drug development process. We are delighted to collaborate with KineMed as they provide unique clinical insights into drug target engagement and processes of disease modification that can advantage Camino in accomplishing these goals.”
About Camino Partnership, LLC
Camino was formed to provide a more effective and agile alternative to classical drug development strategies. It seeks to align external capital, multiple de-risking strategies and technologies and to operate through a network of externalized service advisors and consultants, to optimize capital efficiency. Camino focuses primarily but not exclusively in the oncology area and typically in the early-mid development stage. Camino intends to maximize return to investors by focusing on early de-risking signal detection to allow early but informed discontinuation of assets (an early kill strategy) as appropriate and redeployment of allocated capital to de-risked assets. Additional information on Camino Partnership, LLC may be found at http://www.globalbiopharmopportunity.com/about-2/.
About KineMed, Inc.
KineMed is a life sciences company that has developed a platform technology with broad applications in drug development. Using its dynamic proteomic technology, KineMed has developed analytic tests that measure, in a single sample, the rate of change of critical biological pathways. KineMed has the unique ability to measure the effects of drugs on the production and destruction of key molecules involved in health and disease-modifying biological processes to provide meaningful, and previously unavailable, rapid proof-of-concept clinical studies.
For more information about KineMed, please visit: www.kinemed.com
Help employers find you! Check out all the jobs and post your resume.